Novo Nordisk is a Denmark-based pharmaceutical company best known for developing and supplying medicines for diabetes, obesity and other serious chronic conditions. Its therapeutic capabilities include peptide and protein-based treatments alongside clinical development and manufacturing. Official investor material lists B shares on Nasdaq Copenhagen and American depositary receipts on the New York Stock Exchange under NVO. These listings refer to the same group and should be mapped as a single issuer.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Novo Nordisk is a Denmark-based pharmaceutical company best known for developing and supplying medicines for diabetes, obesity and other serious chronic conditions. Its therapeutic capabilities include peptide and protein-based treatments alongside clinical development and manufacturing. Official investor material lists B shares on Nasdaq Copenhagen and American depositary receipts on the New York Stock Exchange under NVO. These listings refer to the same group and should be mapped as a single issuer.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Works with Orbis on oral macrocycle discovery and with Vivtex on delivery. Success with oral semaglutide does not automatically validate the collaborative macrocycle program.
Business, technology & evidence
Novo Nordisk is a Denmark-based pharmaceutical company best known for developing and supplying medicines for diabetes, obesity and other serious chronic conditions. Its therapeutic capabilities include peptide and protein-based treatments alongside clinical development and manufacturing. Official investor material lists B shares on Nasdaq Copenhagen and American depositary receipts on the New York Stock Exchange under NVO. These listings refer to the same group and should be mapped as a single issuer.
SecuritiesNasdaq Copenhagen: NOVO B / NYSE: NVO
Program / service
Target / indication
Representative stage
Evidence & scope
Orbis–Novo macrocycle program
Not disclosed · Cardiometabolic
未披露
Human results not disclosed
Vivtex–Novo delivery collaboration
Not disclosed · Metabolic diseases
未披露
Human results not disclosed
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Korro disclosed that Novo Nordisk gave termination notice on November 3 for their research and license agreement, effective February 1, 2027. The collaboration had been paused since November 2025. Korro received a $10 million upfront payment and research-cost reimbursements, but earned no milestones. The notice concerns this specific agreement rather than all of Korro's RNA-editing programs.
Orbis Medicines and Novo Nordisk signed a multi-target discovery and licensing agreement for orally bioavailable macrocycles in cardiometabolic disease. Orbis is eligible for up to $1.4 billion in upfront and future milestone payments, plus royalties, and Novo will make a strategic investment. Separate upfront and investment amounts were undisclosed; the headline value is not cash already paid.
